The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The evaluation committee considered evidence submitted by Eli Lilly, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for ...

The phase III data from the LIBRETTO clinical trial have confirmed the importance of selective RET (REarranged during ...

Approximately 1%–2% of all NSCLC cases carry a RET fusion that stimulates oncogenic activity and promotes unchecked cellular proliferation. Selpercatinib is a RET kinase inhibitor approved in the US ...

Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival. If you have the appropriate software installed, you can download article citation data to ...

Selpercatinib, a first-in-class, potent RET kinase inhibitor with central nervous system activity, shows sustained, significant improvements in progression-free survival (PFS) and overall survival (OS ...

Please provide your email address to receive an email when new articles are posted on . Among patients with RET-fusion positive non-small cell lung cancer, selpercatinib was well tolerated and ...

Please provide your email address to receive an email when new articles are posted on . Selpercatinib conferred a markedly higher objective response rate compared with control treatment.

INDIANAPOLIS, Aug. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced topline results from the LIBRETTO-431 study evaluating Retevmo versus platinum-based chemotherapy plus pemetrexed ...

Treatment with selpercatinib (LOXO-292) was associated with high objective response rate (ORR) in heavily pretreated patients with RET fusion-positive non-small cell lung cancer (NSCLC), according to ...

The evaluation committee considered evidence submitted by Eli Lilly, a review of this submission by the evidence assessment group (EAG), and responses from stakeholders. See the committee papers for ...